PRINCETON, NJ--(Marketwire - May 4, 2012) - Agile Therapeutics, a pharmaceutical company focused on developing and commercializing more convenient women's contraceptive products, today announced that it has been named as a finalist for the "Life Sciences Company of the Year" Enterprise Award by the Greater Philadelphia Alliance for Capital and Technologies (PACT), a not-for-profit organization for emerging growth companies in the information technology, clean technology, and life sciences industries. Agile's President and CEO Al Altomari attended the award ceremony during the 19th annual Enterprise Awards hosted by PACT on May 3, 2012 at the Hilton Philadelphia City Line.
The PACT Enterprise Awards are given annually to publicly recognize and celebrate Greater Philadelphia's up and coming and most successful organizations. The PACT Awards honor the Greater Philadelphia region's top technology and life sciences companies and entrepreneurs.
Agile was nominated for "Life Science Company of the Year" based on its development of AG200-15, a low-dose, once-weekly combination hormonal contraceptive patch that recently completed Phase III trials and for which Agile recently submitted a new drug application (NDA) with the Food and Drug Administration (FDA). The nomination recognizes the product's potential impact on the market, the company's ability to raise capital, generate revenue, and commercialize to enter into substantive strategic alliances, and the company's clinical pathway to development.
"We are honored to receive this recognition from the Greater Philadelphia Alliance for Capital and Technologies. Being named a finalist for the 2012 'Life Sciences Company of the Year' by this prestigious organization is a testament to the hard work and dedication of the entire Agile team and its commitment to developing more convenient contraceptive options for women," said Al Altomari, President and CEO of Agile Therapeutics Inc. "We are working diligently to bring AG200-15 to women looking for safe, effective and convenient contraceptive options."
About Agile Therapeutics
Agile Therapeutics is a pharmaceutical development company specializing in Women's Healthcare products, with an initial focus on providing women with more options and more convenient methods of hormonal contraception. The company's lead product, AG200-15, is a once-weekly contraceptive patch that recently completed Phase III clinical trials. In addition, Agile is also developing a low dose, progestin-only contraceptive patch, AG890 (formerly AG900). Both AG200-15 and AG890 incorporate proprietary transdermal delivery technology, Skinfusion®, developed by Agile, consisting of an active and peripheral adhesive system that allows stable drug delivery and dependable adhesion over seven days. For more information, please visit http://www.agiletherapeutics.com.
About the Greater Philadelphia Alliance for Capital and Technologies
Greater Philadelphia Alliance for Capital and Technologies (PACT)'s vision is to be a premier resource for emerging growth companies in the information technology, clean technology, and life sciences industries. We connect emerging growth companies, venture investors, professional advisors, and technology-focused corporations to network, develop relationships, pursue business opportunities, and market and promote their businesses to foster growth and innovation.
The Enterprise Awards remain the Greater Philadelphia region's most prestigious business honors for technology and life sciences companies, leaders, and entrepreneurs. Attracting more than 1,200 prominent business leaders, the Enterprise Awards black-tie gala celebrates achievement, innovation, and success in the Greater Philadelphia region. For more information on PACT's Enterprise Awards, please visit http://pact.gpcc.com/.